Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 5
2008 10
2009 12
2010 18
2011 94
2012 168
2013 195
2014 210
2015 152
2016 65
2017 33
2018 12
2019 6
2020 11
2021 10
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

890 results

Results by year

Filters applied: . Clear all
Page 1
Boceprevir.
Rizza SA, Talwani R, Nehra V, Temesgen Z. Rizza SA, et al. Drugs Today (Barc). 2011 Oct;47(10):743-51. doi: 10.1358/dot.2011.47.10.1656503. Drugs Today (Barc). 2011. PMID: 22076489 Review.
Phase I trials of boceprevir demonstrated favorable pharmacokinetic, metabolic and safety profiles. ...Boceprevir is the first-in-class of an exciting new phase of HCV treatment....
Phase I trials of boceprevir demonstrated favorable pharmacokinetic, metabolic and safety profiles. ...Boceprevir is the first …
Boceprevir.
[No authors listed] [No authors listed] Drugs R D. 2010;10(3):203-10. doi: 10.2165/11586030-000000000-00000. Drugs R D. 2010. PMID: 20945949 Free PMC article. Review.
Boceprevir (SCH 503034; SCH-503034) is a peptidomimetic NS3/4A serine protease inhibitor, representing a new class of hepatitis C virus (HCV) inhibitors. ...Phase III development continues in the US, Europe, and Canada. This review looks at the key development milestones a …
Boceprevir (SCH 503034; SCH-503034) is a peptidomimetic NS3/4A serine protease inhibitor, representing a new class of hepatitis C vir …
Boceprevir.
[No authors listed] [No authors listed] Prescrire Int. 2012 Apr;21(126):89-92. Prescrire Int. 2012. PMID: 22515132
In clinical trials, addition of boceprevir did not increase efficacy when the peginterferon alfa-2b + ribavirin combination reduced viral load during the first 4 weeks of treatment. ...Boceprevir is a potent inhibitor of cytochrome P450 isoenzyme CYP3A4; clinically …
In clinical trials, addition of boceprevir did not increase efficacy when the peginterferon alfa-2b + ribavirin combination reduced v …
Boceprevir: a user's guide.
Kwo PY, Zhao R. Kwo PY, et al. Clin Liver Dis. 2011 Aug;15(3):537-53. doi: 10.1016/j.cld.2011.05.005. Clin Liver Dis. 2011. PMID: 21867935 Review.
Recent data have demonstrated promise for the NS3 protease inhibitor boceprevir, which, when added to the standard of care peginterferon and ribavirin, improves sustained virological response while shortening duration of therapy in genotype-1-infected individuals. This rev …
Recent data have demonstrated promise for the NS3 protease inhibitor boceprevir, which, when added to the standard of care peginterfe …
Boceprevir and treatment of chronic hepatitis C.
Kwo PY. Kwo PY. Clin Liver Dis. 2013 Feb;17(1):63-72. doi: 10.1016/j.cld.2012.09.005. Clin Liver Dis. 2013. PMID: 23177283 Review.
Boceprevir is effective in treatment naive, relapsers, partial responders, and null responders. Those with advanced fibrosis require 44 weeks of boceprevir therapy after a 4-week peg/ribavirin lead-in. The main side effect with boceprevir is anemia and ribavi …
Boceprevir is effective in treatment naive, relapsers, partial responders, and null responders. Those with advanced fibrosis require …
Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
Foote BS, Spooner LM, Belliveau PP. Foote BS, et al. Ann Pharmacother. 2011 Sep;45(9):1085-93. doi: 10.1345/aph.1P744. Epub 2011 Aug 9. Ann Pharmacother. 2011. PMID: 21828346 Review.
Boceprevir displays linear pharmacokinetics and is rapidly absorbed upon oral administration. ...Safety analyses showed an increased incidence of adverse effects when boceprevir was used with Peg-IFN-alpha-2b and ribavirin. The most common adverse events reported in …
Boceprevir displays linear pharmacokinetics and is rapidly absorbed upon oral administration. ...Safety analyses showed an increased …
A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J. Jacobson IM, et al. J Viral Hepat. 2012 May;19 Suppl 2:1-26. doi: 10.1111/j.1365-2893.2012.01590.x. J Viral Hepat. 2012. PMID: 22404758 Review.
The aim of this study is to review clinical trial data on the newly approved protease inhibitors boceprevir and telaprevir to develop consensus recommendations on the optimal use of these agents for the treatment of patients with chronic hepatitis C virus (HCV) infection. …
The aim of this study is to review clinical trial data on the newly approved protease inhibitors boceprevir and telaprevir to develop …
Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.
Lam JT, Jacob S. Lam JT, et al. Am J Health Syst Pharm. 2012 Dec 15;69(24):2135-9. doi: 10.2146/ajhp110500. Am J Health Syst Pharm. 2012. PMID: 23230035 Review.
Due to the potential for serious or potentially life-threatening adverse events, boceprevir use is contraindicated in patients receiving any of a wide range of drugs whose clearance is highly dependent on cytochrome P-450 (CYP) isoenzymes 3A4/5 (e.g., cisapride, lovastatin …
Due to the potential for serious or potentially life-threatening adverse events, boceprevir use is contraindicated in patients receiv …
Boceprevir: a protease inhibitor for the treatment of hepatitis C.
Chang MH, Gordon LA, Fung HB. Chang MH, et al. Clin Ther. 2012 Oct;34(10):2021-38. doi: 10.1016/j.clinthera.2012.08.009. Epub 2012 Sep 11. Clin Ther. 2012. PMID: 22975763 Review.
Additional information was obtained from the US Food and Drug Administration's Web site, review of the reference lists of identified articles, and posters and abstracts from scientific meetings. RESULTS: Clinical efficacy of boceprevir was assessed in 2 Phase III trials, S …
Additional information was obtained from the US Food and Drug Administration's Web site, review of the reference lists of identified article …
Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.
Klibanov OM, Vickery SB, Olin JL, Smith LS, Williams SH. Klibanov OM, et al. Pharmacotherapy. 2012 Feb;32(2):173-90. doi: 10.1002/PHAR.1046. Pharmacotherapy. 2012. PMID: 22392426 Review.
Data with boceprevir in HIV-HCV-coinfected patients are currently lacking; however, initial data on drug-drug interactions between boceprevir and antiretrovirals have become available. Resistance to boceprevir has been evaluated in trials as well, although mo …
Data with boceprevir in HIV-HCV-coinfected patients are currently lacking; however, initial data on drug-drug interactions between …
890 results